Effects of an Omega-3 Fatty Acid-based Supplement on Healthy Ageing

Healthy Aging Clinical Trial

Official title: Tolerability and Effects of a New Omega-3 Fatty Acid-based Supplement on Clinical and Biological Markers of Healthy Ageing

Status Recruiting

Clinical Trial Summary

The goal of this randomised, double-blind placebo controlled trial is to explore tolerability and the effects of a new omega-3 fatty acid-based supplement on biological and clinical aspects relevant for healthy ageing.

Participants will be asked to take a supplement or a placebo for 6 months, and to attend the clinic a total of 3 times and to perform or submit the following:

• Physical examination

• Muscle function tests

• Cognitive testing

• Questionnaire completion

• Biological samples, including blood, saliva and faeces.

Researchers will compare the results from the group taking the supplement to the results of the group taking a placebo to see if the supplement has an effect on biological and clinical aspects associated with healthy ageing.

Clinical Trial Description

Healthy ageing is the process of developing and maintaining the functional ability that is associated with wellbeing across the life course and comprises mental and physical capacities such as the ability to walk, think, see, hear and remember. These factors are influenced by several factors including diseases, age-related decline in organ function and lifestyle such as diet and physical exercise.

Among dietary factors, omega-3 fatty acids, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are increasingly recognized as potentially promoting healthy ageing, including benefits to cardiovascular system, as well as muscle function, and brain function. It is also important for brain and eye development. Regular supplementation with EPA and DHA therefore potentially offers a range of health benefits throughout life.

Since humans cannot synthesize omega-3 fatty acids, these are considered essential nutrients and must be incorporated into the diet, with the main source for EPA and DHA incorporation being fish oils and supplementation. Western diets are often deficient in these compounds, therefore, regular supplementation with EPA and DHA potentially delays functional decline in ageing and reduces the incidence / severity of age-related diseases.

Objective/Aims:

Explore tolerability and the effects of the IP on biological and clinical aspects relevant for healthy aging.

Design:

Randomized, double-blind placebo-controlled parallel-group trial for six months. ;

Related Conditions & MeSH terms

• Healthy Aging

• NCT number: NCT06150261
• Study type: Interventional
• Source: Helse Stavanger HF
• Contact: Dag Aarsland, PhD
• Phone: +47 51515062
• Email: dag.arsland@sus.no
• Status: Recruiting
• Phase: N/A
• Start date: December 8, 2023
• Completion date: December 31, 2025